A Partially-Blind Multi-Centric Study in Adults Aged Between 18-60 Yrs Designed to Evaluate the Reactogenicity & Immunogenicity of 1 [and] 2 Doses of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) Administered at Different Doses [and] Adjuvanted or Not.

Trial Profile

A Partially-Blind Multi-Centric Study in Adults Aged Between 18-60 Yrs Designed to Evaluate the Reactogenicity & Immunogenicity of 1 [and] 2 Doses of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) Administered at Different Doses [and] Adjuvanted or Not.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Dec 2006 Status change
    • 04 Apr 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top